GET DAILY SIGNALSWhy Is ADMA Biologics (ADMA) Stock Up +26.05% Today?
Key Takeaways
- ADMA shares surged roughly 26% in Thursday's session, climbing to about $13.21 from a prior close of $10.48.
- The move was driven by a third-quarter earnings beat, with revenue and adjusted EPS topping consensus estimates.
- Flagship product ASCENIV posted 31% revenue growth, while gross margin expanded sharply to 71% from 56%.
- Management raised its full-year 2026 adjusted net income and adjusted EBITDA guidance, reinforcing the bullish case.
- The rally pushed the stock back above its 50-day and 200-day moving averages, triggering renewed momentum and short-covering.
- For more detail, explore Price Targets, Earnings, and Forecast pages on the ticker's profile.
- Discover the strongest performers under current conditions by exploring Trending AI Robots.
Opening Summary
ADMA Biologics, Inc. (ADMA), a U.S.-based biopharmaceutical company focused on manufacturing and marketing specialty plasma-derived biologics, delivered one of the strongest single-day performances in the sector on Thursday. Shares climbed about 26.05% to roughly $13.21, up from the prior session's close of $10.48. The sharp rally followed a third-quarter earnings report that beat Wall Street expectations, driven by accelerating demand for its lead product and a substantial expansion in profitability.
Earnings Beat and Margin Expansion
The primary catalyst was a top-and-bottom-line beat for the third quarter. ADMA reported revenue of $141.1 million, up 5% year over year and ahead of the roughly $138.1 million consensus. Adjusted earnings came in at $0.23 per share, exceeding the $0.20 estimate, while GAAP net income rose 37% to $49.9 million, or $0.22 per share.
Investors responded most forcefully to the dramatic improvement in profitability. Gross margin expanded approximately 1,450 basis points to 71% from 56% a year earlier, reflecting a favorable shift toward higher-margin products and gains from yield-enhanced manufacturing. Adjusted EBITDA increased 32% to $77.3 million.
ASCENIV Momentum and Raised Guidance
The company's flagship therapy, ASCENIV, a plasma-derived antibody treatment for primary immunodeficiency, was the standout driver. ASCENIV revenue climbed 31% year over year to $124.7 million, now representing about 88% of total revenue, supported by growing physician adoption, new patient starts, and rising utilization. Management said favorable demand trends continued into the fourth quarter.
Bucking the trend, revenue from BIVIGAM, another immune globulin product, declined to $15.4 million amid competitive pricing pressure, though management noted early signs of stabilization in underlying demand.
Against this backdrop, ADMA reiterated its full-year 2026 revenue outlook of at least $530 million while raising its minimum adjusted net income guidance to $180 million and its adjusted EBITDA outlook to $275 million. The improved guidance reinforced confidence in the company's margin trajectory.
Pipeline Progress and Analyst Response
Beyond the core results, the company highlighted constructive FDA feedback on its pre-investigational new drug meeting for SG-001, an investigational pneumococcal hyperimmune globulin candidate. ADMA plans to incorporate the regulator's recommendations and advance toward an investigational new drug submission. Analyst Cantor Fitzgerald maintained a Neutral rating while raising its price target to $13 from $12, a modest acknowledgment of the improved fundamentals.
Market Context and Trading Activity
The move had a strong technical dimension as well. The surge carried ADMA back above both its 50-day and 200-day moving averages in a single session, levels the stock had struggled to reclaim following a steep 2026 drawdown tied to a short-seller report. Volume was markedly elevated relative to recent averages, consistent with a re-rating combined with short-covering as bearish positions were squeezed by the earnings-driven rally.
The action was largely company-specific rather than a broad healthcare-sector move, underscoring that the results and guidance — not macro conditions — were the dominant force behind the price action.
What Comes Next for ADMA
Looking ahead, traders will focus on whether the stock can hold above its reclaimed moving averages and sustain the post-earnings momentum. Key items on the horizon include further ASCENIV utilization data, the progression of the SG-001 regulatory pathway, and upcoming clinical findings the company plans to share at the ACAAI Annual Conference. Risks remain, including continued pricing pressure in the BIVIGAM franchise, elevated accounts receivable, and lingering concerns tied to the earlier short-seller allegations. Analyst expectations will also be a focal point as the market digests the company's higher guidance and margin outlook.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots, chosen from hundreds of bots covering thousands of tickers for their strength under current market conditions. The featured bots vary by strategy, timeframe, performance metrics, and traded symbols, offering traders a way to explore data-driven approaches across different market environments. Explore the page to see which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ADMA saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for ADMA moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 65 similar instances where the indicator exited the overbought zone. In 51 of the 65 cases the stock moved lower. This puts the odds of a downward move at 78%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ADMA moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 28 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
ADMA broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on ADMA as a result. In 73 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for ADMA just turned positive on November 05, 2026. Looking at past instances where ADMA's MACD turned positive, the stock continued to rise in 43 of 49 cases over the following month. The odds of a continued upward trend are 88%.
Following a +5.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADMA advanced for three days, in 245 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 210 of 254 cases where ADMA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 25 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ADMA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 40 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 55 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.985) is normal, around the industry mean (3.482). P/E Ratio (17.681) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.170) is also within normal values, averaging (440.869).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an operator of a specialty immune globulin, development and commercialization of human plasma and plasma-derived therapeutics
Industry Biotechnology
Advertisement